Specifically, many studies have shown that the increased activation of NRF2 in cancer cells leads to its augmented transcriptional activity and promotes tumor progression [12,13,14], metastasis formation [15], resistance to chemo-radiotherapy [16,17,18,19], and is clinically associated with poor prognosis [20]. The gene discussed is NFE2L2; the disease is cancer.